PriceTargets.com logo

Nurix Therapeutics - NRIX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.40
  • Forecasted Upside: 20.34%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$24.43 As of 10/30/2024 03:53 PM ET
▼ -0.77 (-3.06%)

This chart shows the closing price for NRIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nurix Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRIX

Analyst Price Target is $29.40
▲ +20.34% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $29.40, with a high forecast of $41.00 and a low forecast of $10.00. The average price target represents a 20.34% upside from the last price of $24.43.

This chart shows the closing price for NRIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Nurix Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2024UBS GroupInitiated CoverageBuy$35.00
10/21/2024HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $30.00
10/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
10/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$27.00 ➝ $26.00
10/14/2024StephensReiterated RatingOverweight ➝ Overweight$31.00 ➝ $31.00
10/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
10/11/2024Jefferies Financial GroupInitiated CoverageBuy$41.00
9/6/2024Robert W. BairdInitiated CoverageOutperform$26.00
9/4/2024OppenheimerBoost TargetOutperform ➝ Outperform$27.00 ➝ $30.00
8/14/2024OppenheimerBoost TargetOutperform ➝ Outperform$25.00 ➝ $27.00
7/31/2024Truist FinancialInitiated CoverageBuy$36.00
7/15/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$31.00 ➝ $34.00
7/15/2024BarclaysBoost TargetOverweight ➝ Overweight$20.00 ➝ $31.00
7/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$26.00 ➝ $27.00
7/12/2024Needham & Company LLCLower TargetBuy ➝ Buy$31.00 ➝ $29.00
6/27/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$23.00 ➝ $26.00
6/18/2024HC WainwrightBoost TargetBuy ➝ Buy$19.00 ➝ $26.00
6/17/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$30.00 ➝ $31.00
6/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
6/5/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$35.00 ➝ $35.00
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$27.00
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
5/14/2024StephensInitiated CoverageOverweight$20.00
4/11/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$22.00 ➝ $23.00
4/11/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$24.00 ➝ $25.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
4/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
2/26/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $10.00
2/20/2024HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $19.00
2/16/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$23.00 ➝ $20.00
2/16/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$24.00 ➝ $22.00
2/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
2/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
11/2/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$29.00 ➝ $24.00
10/13/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$30.00 ➝ $29.00
10/13/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
9/8/2023HC WainwrightBoost TargetBuy ➝ Buy$33.00 ➝ $35.00
9/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$31.00
7/24/2023HC WainwrightLower TargetBuy$53.00 ➝ $33.00
4/21/2023Needham & Company LLCReiterated RatingBuy$31.00
4/14/2023Needham & Company LLCReiterated RatingBuy$31.00
4/14/2023Royal Bank of CanadaReiterated RatingOutperform$30.00
3/21/2023HC WainwrightReiterated RatingBuy$53.00
3/9/2023BarclaysInitiated CoverageOverweight$20.00
2/27/2023OppenheimerInitiated CoverageOutperform$25.00
2/14/2023Stifel NicolausLower TargetBuy$37.00 ➝ $31.00
2/13/2023JPMorgan Chase & Co.Lower TargetOverweight$37.00 ➝ $36.00
2/10/2023HC WainwrightReiterated RatingBuy$53.00
2/10/2023Royal Bank of CanadaLower TargetOutperform$39.00 ➝ $30.00
2/10/2023Needham & Company LLCLower TargetBuy$32.00 ➝ $31.00
12/13/2022Leerink PartnersLower TargetOutperform$37.00 ➝ $28.00
10/13/2022HC WainwrightLower Target$53.00
10/11/2022Morgan StanleyInitiated CoverageEqual Weight$11.00
10/7/2022HC WainwrightLower TargetBuy$54.00 ➝ $53.00
7/12/2022Needham & Company LLCLower TargetBuy$38.00 ➝ $32.00
7/11/2022HC WainwrightLower TargetBuy$60.00 ➝ $54.00
7/8/2022Stifel NicolausLower Target$44.00 ➝ $37.00
7/8/2022JPMorgan Chase & Co.Lower TargetOverweight$46.00 ➝ $37.00
7/8/2022Robert W. BairdLower TargetOutperform$41.00 ➝ $32.00
5/31/2022Piper SandlerLower Target$55.00 ➝ $35.00
5/31/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$25.00
5/27/2022Needham & Company LLCLower TargetBuy$48.00 ➝ $38.00
4/18/2022Royal Bank of CanadaLower TargetOutperform$42.00 ➝ $39.00
4/14/2022HC WainwrightLower TargetBuy$62.00 ➝ $60.00
4/11/2022Wells Fargo & CompanyLower TargetEqual Weight$28.00 ➝ $25.00
2/10/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00
1/28/2022Robert W. BairdLower Target$49.00 ➝ $41.00
1/5/2022Needham & Company LLCReiterated RatingBuy$48.00
12/29/2021HC WainwrightInitiated CoverageBuy$62.00
10/28/2021Robert W. BairdBoost TargetOutperform$46.00 ➝ $49.00
10/27/2021Leerink PartnersBoost TargetAverage ➝ Outperform$50.00 ➝ $64.00
10/14/2021Leerink PartnersInitiated CoverageOutperform$50.00
7/15/2021Needham & Company LLCInitiated CoverageBuy$48.00
4/30/2021Royal Bank of CanadaInitiated CoverageOutperform$42.00
4/14/2021Berenberg BankInitiated CoverageBuy
2/17/2021Needham & Company LLCReiterated RatingBuy$44.00
2/17/2021Piper SandlerBoost TargetOverweight$40.00 ➝ $60.00
1/29/2021JPMorgan Chase & Co.Boost TargetOverweight$34.00 ➝ $56.00
1/8/2021Needham & Company LLCBoost TargetBuy$35.00 ➝ $44.00
11/18/2020Robert W. BairdInitiated CoverageOutperform$40.00
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
8/18/2020Stifel NicolausInitiated CoverageBuy$34.00
8/18/2020Needham & Company LLCInitiated CoverageBuy$35.00
8/18/2020Piper SandlerInitiated CoverageOverweight$40.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/3/2024
  • 2 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 13 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 13 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nurix Therapeutics logo
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $24.43
Low: $24.21
High: $25.41

50 Day Range

MA: $24.18
Low: $21.54
High: $26.45

52 Week Range

Now: $24.43
Low: $4.96
High: $27.60

Volume

494,071 shs

Average Volume

884,594 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Nurix Therapeutics?

The following equities research analysts have issued stock ratings on Nurix Therapeutics in the last year: Barclays PLC, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stephens, Stifel Nicolaus, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for NRIX.

What is the current price target for Nurix Therapeutics?

15 Wall Street analysts have set twelve-month price targets for Nurix Therapeutics in the last year. Their average twelve-month price target is $29.40, suggesting a possible upside of 20.3%. Jefferies Financial Group Inc. has the highest price target set, predicting NRIX will reach $41.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $10.00 for Nurix Therapeutics in the next year.
View the latest price targets for NRIX.

What is the current consensus analyst rating for Nurix Therapeutics?

Nurix Therapeutics currently has 1 hold rating and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NRIX.

What other companies compete with Nurix Therapeutics?

Other companies that are similar to Nurix Therapeutics include Praxis Precision Medicines, Arvinas, Ligand Pharmaceuticals, COMPASS Pathways and Blueprint Medicines. Learn More about companies similar to Nurix Therapeutics.

How do I contact Nurix Therapeutics' investor relations team?

The company's listed phone number is 415-660-5320 and its investor relations email address is [email protected]. The official website for Nurix Therapeutics is www.nurixtx.com. Learn More about contacing Nurix Therapeutics investor relations.